Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
1.075
+0.005 (0.47%)
Nov 21, 2024, 11:20 AM EST - Market open
Immunic Employees
Immunic had 77 employees as of December 31, 2023. The number of employees increased by 11 or 16.67% compared to the previous year.
Employees
77
Change (1Y)
11
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,258,494
Market Cap
96.83M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| FONAR | 520 |
| Karyopharm Therapeutics | 325 |
| Coherus BioSciences | 306 |
| PetMed Express | 287 |
| Generation Bio Co. | 174 |
| Invivyd | 95 |
| MediciNova | 13 |
| Nuvectis Pharma | 13 |
IMUX News
- 8 days ago - Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology - PRNewsWire
- 12 days ago - Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 21 days ago - Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - PRNewsWire
- 23 days ago - Immunic to Participate in Industry, Scientific and Investor Conferences in November - PRNewsWire
- 4 weeks ago - Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis - PRNewsWire
- 2 months ago - Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis - PRNewsWire
- 2 months ago - Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome - PRNewsWire